Re Research Study

Deltex Medical Group PLC
12 July 2004



12 July 2004

                            Deltex Medical Group plc


Nurse-led randomised trial demonstrates significant reduction in hospital length
      of stay through use of CardioQ on patients following cardiac surgery


Deltex Medical Group plc ('Deltex Medical' / 'Company'), the AIM listed
haemodynamic monitoring company, today announces the publication of the results
of a randomised controlled clinical trial assessing the impact of the use by
nurses of its CardioQ haemodynamic monitor on patients in intensive care and
cardiothoracic units following cardiac surgery.


The study, published by the British Medical Journal on 8 July 2004, concluded
that patients whose circulatory status was optimised using the CardioQ were able
to leave hospital two days earlier than those whose treatment was managed
traditionally. The study also demonstrated a 23% reduction in length of stay in
intensive care - by far the most costly part of a patient's stay in hospital
outside of the operating theatre.


This trial was undertaken by nurses on patients at the University College of
London hospitals in London, working in conjunction with Professor Mervyn Singer
and using treatment protocols developed by medical and nursing staff.


Chief Executive, Andy Hill, commented:


'Once again an independent trial has clearly demonstrated that using the CardioQ
to optimise patient's haemodynamic status following surgery improves patient
outcomes and thereby creates an opportunity to realise significant economic
benefits for health care providers.


'Empowering nurses to use this approach to patient management is an important
step towards delivering better care for more patients in the National Health
Service.  I fully expect this result to further accelerate the adoption of
nurse-led, protocol driven haemodynamic optimisation across the NHS.'




For further information, please contact:-



Deltex Medical Group plc
Nigel Keen, Chairman
[e-mail]
01243 774 837



Andy Hill, Chief Executive
[e-mail]
01243 774 837



Ewan Phillips, Finance Director
[e-mail]
01243 774 837



Financial Dynamics
Stephanie Highett
[e-mail]
020 7831 3113







Notes for Editors



Deltex Medical manufactures and markets the CardioQ monitor, which uses
disposable ultra-sound probes inserted into the oesophagus to determine the
amount of blood being pumped around the body - 'circulating blood volume'.
Reduced circulating blood volume is known as hypovolemia, which leads to
insufficient oxygen being delivered to the organs.  This causes medical
complications including peripheral and major organ failure which can lead to
death.  Hypovolemia, which is akin to severe dehydration, affects virtually
every patient having surgery because of the combined effects of pre-operative
starvation, the impact of the anaesthetic agents and trauma from the surgery
itself.  Using fluids and drugs, guided by the CardioQ, to optimise the amount
of circulating blood significantly reduces post-operative complications allowing
patients to make a faster, more complete recovery and return home earlier.



The CardioQ incorporates the Company's proprietary software and a small
diameter, easy-to-use, minimally invasive, disposable oesophageal probe that is
used for transmitting and receiving an ultra-sound signal. By using this
technology, the CardioQ provides clinicians with the ability to haemodynamically
optimise critically ill patients and those undergoing routine moderate to major
surgery through the controlled administration of fluid and drugs. Haemodynamic
optimisation has been scientifically proven to improve the speed and quality of
patient recovery and reduce hospital stay.


There are over 1,250 CardioQs currently in use in hospitals worldwide and
distribution arrangements are in place in over 30 countries. In addition, there
are currently more than 90 clinical publications on the use of the CardioQ which
have repeatedly:-

  • validated the results of the Monitor against known standards for measuring
    cardiac output, demonstrating that the technology works


  • proved that the CardioQ works in a wide range of surgical procedures


  • demonstrated that the Company's technology provides significant health and
    economic benefits by helping to reduce post-operative complications and
    length of hospital stays by an average of 30 to 40 per cent for a wide range
    of patients.






                      This information is provided by RNS
            The company news service from the London Stock Exchange